Analysts’ mean recommendation for Bristol-Myers Squibb Company’s (BMY) stands at 2.50. The company traded as low as $5.83 on the day. The stock’s 50-day moving average is $65.74 and its 200-day moving average is $67.95. This depreciation has taken its market cap to $94.52B and a price-to-earnings ratio to 33.08. During the same quarter in the prior year, the firm posted $0.53 EPS.
Advertisement
Some buy side analysts are also providing their Analysis on Bristol-Myers Squibb Company, where 5 analysts have rated the stock as Strong buy, 4 analysts have given a Buy signal, 13 said it’s a HOLD, 2 reported it as Underperform and 0 analysts rated the stock as Sell. The business earned $4.90 billion during the quarter, compared to the consensus estimate of $4.60 billion. Over the one year trading period, the stock has a high price of $77.12 and its low price is recorded at $55.11.
On Tuesday, Shares of Bristol-Myers Squibb Co (NYSE:BMY) gained 1.08% to $56.96. EPS growth quarter over quarter is 990.60%, and 17.00% for sales growth quarter over quarter. Earnings per share (EPS) is 1.71, and this is looking to grow in the next year to 15.13% after growing -22.30% this past year. Bristol-Myers Squibb Co makes up approx 0.32% of Cornerstone Advisory Llp’s portfolio.Roanoke Asset Management Corp Ny reduced its stake in BMY by selling 274 shares or 0.4% in the most recent quarter.
Out of 12 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 3 rate it a “Buy”, 2 “Sell”, while 7 “Hold”. The insider owns 371,963 shares which have current market value of around $21041947.ANDREOTTI LAMBERTO is another major inside shareholder in the company. The company had revenue of $4.90 billion for the quarter, compared to analysts’ expectations of $4.60 billion.
Investors should note that on Aug 3, 2016, Bristol-Myers Squibb Co announced a cash dividend of $0.3800. The ex-dividend date is Wednesday, October 5th.
Share prices sometimes get a bounce to the upside when analysts reiterate coverage. The 20 stock analysts who cover the stock have an average PT at $68.75, with individual targets in the range of $48 to $100. They now own 1.19 billion shares or 3.56% less from 1.23 billion shares in 2016Q1. Bank of Montreal Can acquired a new position in Bristol-Myers Squibb during the second quarter worth approximately $154,732,000. Geode Capital Management LLC raised its position in shares of Bristol-Myers Squibb by 1.9% in the first quarter.
Shares of Sophiris Bio, Inc.
08/10/2016 – Bristol-Myers Squibb Company had its “buy” rating reiterated by analysts at Argus.
The ability for Bristol-Myers Squibb Company, to deal with debt, means it current ratio is 1.6, and quick ratio is 1.4.
Advertisement
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
